The Vector
Strategic Intelligence for Life Science Executives
The Vector is a new executive publication created specifically for senior life sciences leaders across commercial, market access, HEOR, and medical affairs. Unlike most industry newsletters, this isn’t a recap of headlines or policy updates. Instead, we leverage RPR, our stakeholder engagement solution, to capture unique insights that we can share with senior industry professionals.
Please get in touch if you’d like to learn more about this research or how our experts can help support your own.
The LATEST issue
In our second issue, we surveyed 33 payers across 11 non‑US markets to understand how renewed US interest in Most‑Favored‑Nation (MFN) drug pricing could reshape pricing, reimbursement, and access globally. Specifically, we asked payers about their views on:
- Expected impact on national drug pricing and access
- Anticipated manufacturer response and the implications on payer decision-making
- Country-level spillover on new product launches and impact on launch sequencing and delays
Access Vector 2 (14.7.26)
Our first issue
For the inaugural issue, we surveyed and engaged US payers directly to understand how they are thinking about AI right now:
- How do they currently use AI?
- How quickly are they moving to adopt it for what other uses?
- How manufacturers can prepare for success?
Access Vector Issue 1
Headquarters:
HOBOKEN
111 River Street, Suite 1120
Hoboken, New Jersey 07030, US
